Related Experiment Video
Updated: Aug 27, 2025

07:55
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
Published on: October 17, 2015
11.9K
Pin1 and Alzheimer's disease
1Department of Pathology, UT Southwestern Medical Center, 5333 Harry Hines Blvd, Dallas, TX 75390.
Translational Research : the Journal of Laboratory and Clinical Medicine
|September 26, 2022
Summary
Pin1 protein dysfunction is a key factor in Alzheimer's disease (AD) development. This review explores Pin1's function and its critical role in neurodegeneration, offering potential therapeutic insights.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Alzheimer's disease (AD) presents a significant and increasing global health challenge.
- Despite extensive research, the exact causes of AD remain unclear, and effective treatments are lacking.
- Recent findings highlight the loss-of-function of Pin1, a peptidyl prolyl isomerase, as a crucial element in AD pathogenesis.
Purpose of the Study:
- To review the known functions of the Pin1 protein.
- To elucidate the specific role of Pin1 dysfunction in the progression of Alzheimer's disease.
- To discuss the implications of Pin1 in neurodegeneration.
Main Methods:
- Literature review of existing studies on Pin1 and Alzheimer's disease.
- Analysis of biochemical pathways involving Pin1.
- Synthesis of current knowledge on Pin1's role in neurodegenerative processes.
Main Results:
- Pin1 is a unique enzyme catalyzing cis-trans isomerization of specific peptide bonds.
- Loss-of-function or dysfunction of Pin1 is implicated as an early and critical step in AD pathogenesis.
- Pin1's activity is essential for maintaining neuronal health and function.
Conclusions:
- Pin1 dysfunction represents a significant factor in Alzheimer's disease pathology.
- Understanding Pin1's role in neurodegeneration may lead to novel therapeutic strategies for AD.
- Targeting Pin1 could offer a new avenue for treating Alzheimer's disease.
Related Concept Videos
Alzheimer's Disease: Overview
635
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
635
Alzheimer's Disease: Treatment
248
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
248

